MILRINONE LACTATE

Post-LOE

milrinone lactate

Hikma

ANDAINJECTIONINJECTABLE

Approved

May 2002

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

MILRINONE LACTATE (milrinone lactate) by Hikma is clinical pharmacology milrinone is a positive inotrope and vasodilator, with little chronotropic activity different in structure and mode of action from either the digitalis glycosides or catecholamines. First approved in 2002.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Milrinone is a positive inotrope and vasodilator, with little chronotropic activity different in structure and mode of action from either the digitalis glycosides or catecholamines. Milrinone, at relevant inotropic and vasorelaxant concentrations, is a selective inhibitor of…

Indications

Worked on MILRINONE LACTATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.